In a multicenter prospective cohort of cancer patients (CP; n = 840) and healthcare workers (HCWs; n = 935) vaccinated against COVID-19, we noticed the following: i/after vaccination, 4.4% of HCWs and 5.8% of CP were infected; ii/no characteristic was associated with post-vaccine COVID-19 infections among HCWs; iii/CP who developed infections were younger, more frequently women (NS), more frequently had gastrointestinal, gynecological, or breast cancer and a localized cancer stage; iv/CP vaccinated while receiving chemotherapy or targeted therapy had (NS) more breakthrough infections after vaccination than those vaccinated after these treatments; the opposite was noted with radiotherapy, immunotherapy, or hormonotherapy; v/most COVID-19 infections occurred either during the Alpha wave (11/41 HCW, 20/49 CP), early after the first vaccination campaign started, or during the Omicron wave (21/41 HCW, 20/49 CP), more than 3 months after the second dose; vi/risk of infection was not associated with values of antibody titers; vii/the outcome of these COVID-19 infections after vaccination was not severe in all cases. To conclude, around 5% of our CPs or HCWs developed a COVID-19 infection despite previous vaccination. The outcome of these infections was not severe.
在一项针对接种COVID-19疫苗的癌症患者（CP；n = 840）和医护人员（HCWs；n = 935）的多中心前瞻性队列研究中，我们观察到以下结果：一、接种疫苗后，4.4%的医护人员和5.8%的癌症患者发生感染；二、医护人员中未发现任何特征与疫苗后COVID-19感染相关；三、发生感染的癌症患者更年轻、女性比例更高（无统计学显著性），且更常见于患有胃肠道、妇科或乳腺癌以及处于局部癌症分期的患者；四、在接受化疗或靶向治疗期间接种疫苗的癌症患者，其疫苗后突破性感染发生率（无统计学显著性）高于在这些治疗结束后接种的患者；而接受放疗、免疫治疗或激素治疗的患者则呈现相反趋势；五、大多数COVID-19感染发生在Alpha变异株流行期（医护人员11/41例，癌症患者20/49例），即首次疫苗接种活动启动初期，或发生在Omicron变异株流行期（医护人员21/41例，癌症患者20/49例），此时距第二剂疫苗接种已超过3个月；六、感染风险与抗体滴度水平无关联；七、所有病例中疫苗接种后发生的COVID-19感染均未导致严重临床结局。综上所述，约5%的癌症患者和医护人员在接种疫苗后仍发生COVID-19感染，但这些感染均未发展为重症。
肿瘤(癌症)患者之家